Hepatitis C virus (HCV) is one of the main causes of liver disease worldwide. Liver steatosis is a common finding in many hepatic and extrahepatic disorders, the most common being metabolic syndrome (MS). Over time, it has been shown that the frequent coexistence of these two conditions is not coincidental, since many epidemiological, clinical, and experimental studies have indicated HCV to be strongly associated with liver steatosis and numerous metabolic derangements. Here, we present an overview of publications that provide clinical evidence of the metabolic effects of HCV and summarize the available data on the pathogenetic mechanisms of this association. It has been shown that HCV infection can induce insulin resistance (IR) in the liver and peripheral tissues through multiple mechanisms. Substantial research has suggested that HCV interferes with insulin signaling both directly and indirectly, inducing the production of several proinflammatory cytokines. HCV replication, assembly, and release from hepatocytes require close interactions with lipid droplets and host lipoproteins. This modulation of lipid metabolism in host cells can induce hepatic steatosis, which is more pronounced in patients with HCV genotype 3. The risk of steatosis depends on several viral factors (including genotype, viral load, and gene mutations) and host features (visceral obesity, type 2 diabetes mellitus, genetic predisposition, medication use, and alcohol consumption). HCVrelated IR and steatosis have been shown to have a remarkable clinical impact on the prognosis of HCV infection and quality of life, due to their association with resistance to antiviral therapy, progression of hepatic fibrosis, and development of hepatocellular carcinoma. Finally, HCV-induced IR, oxidative stress, and changes in lipid and iron metabolism lead to glucose intolerance, arterial hypertension, hyperuricemia, and atherosclerosis, resulting in increased cardiovascular mortality.
Introduction
Hepatitis C virus (HCV) is a single-stranded RNA virus belonging to the Flaviviridae family. Approximately 64-103 million people are infected with HCV worldwide, making HCV one of the major causes of chronic liver disease.
1 Acute infection may resolve spontaneously in 15%-45% of cases, but the remaining 55%-85% of infected individuals (75%-85% according to serologic surveys) fail to clear the virus and become chronically infected.
1,2 In a significant number of patients, chronic hepatitis C (CHC) will progress to cirrhosis and hepatocellular carcinoma (HCC), which represent the end-stage HCV-related liver disease, and are among the leading causes for liver transplantation in the Western world. 2 Approximately 350,000 to 500,000 people die each year from hepatitis C-related liver diseases around the world. 1 The primary host cells for HCV are hepatocytes, although replication may also occur in other cell types, such as peripheral blood mononuclear cells and B and T lymphocytes. 3, 4 HCV interferes with the hepatic lipid metabolism throughout its life cycle. Viral entry into hepatocytes occurs following its binding to low-density lipoprotein receptors. 5, 6 Once internalized, HCV interferes with the host lipid metabolism for its replication and assembly, which consequently leads to hepatic steatosis. Finally, the virus is released from the hepatocyte via the very low-density lipoprotein secretion pathway. 7 Hepatic steatosis is a condition in which there is excessive accumulation of triglycerides within the hepatocytes. The most common causes are alcohol consumption (alcoholic fatty liver disease) and insulin resistance (IR) within the metabolic syndrome (MS) (non-alcoholic fatty liver disease -NAFLD), but other causes, including malnutrition, total parenteral nutrition, severe weight loss, gastrointestinal bypasses, some inherited metabolic conditions (e.g., abetalipoproteinemia), glycogen storage diseases, lipodystrophy, alpha 1-antitrypsin deficiency, pregnancy, drugs and toxins, as well as human immunodeficiency virus (HIV) and chronic HCV infection, are also responsible for a number of cases.
NAFLD is one of the most common causes of chronic liver disease in the Western world. It represents a spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), where steatosis is associated with hepatic inflammation and various degrees of fibrosis and cirrhosis, which develops as a consequence of long-standing NASH. 8 NAFLD is estimated to affect around 25%-30% of the general population, while NASH is reported in 2%-3% of the population. 9 Strong epidemiological, biochemical, and therapeutic evidence implicate IR as the primary pathophysiological derangement and the key mechanism leading to hepatic steatosis. Indeed, NAFLD is regarded as a hepatic manifestation of the MS.
MS represents a combination of well-known and established cardiovascular disease related risk factors. Multiple definitions of MS exist with several revisions; and although criteria differ, the essential components of MS include insulin resistance/hyperglycemia, dyslipidemia, hypertension, and visceral obesity. [10] [11] [12] [13] [14] These factors have a tendency of clustering together, and individuals with MS have a 2-fold increase in cardiovascular outcomes and a 1.5-fold increase in all-cause mortality. 15 Hepatic steatosis in CHC infection results from the combination of several host and viral factors that directly interfere with lipid metabolism within the hepatocytes or cause different metabolic derangements through IR. Host factors include the before mentioned components of MS, such as obesity and type 2 diabetes mellitus (T2DM); but also include alcohol consumption, medication use, and genetic predisposition (e.g., interleukin (IL) 28B polymorphism). 16, 17 Viral factors include genotype (genotype 3 causing the most pronounced steatosis), HCV RNA load, and gene mutations. [16] [17] [18] HCV and insulin resistance Glucose metabolism impairment, development of IR, and T2DM can often be found accompanying CHC and is commonly measured using the homeostatic model assessment (HOMA) index. Euglycemic insulin clamp studies have shown that IR in CHC has both a hepatic and a peripheral component and induces an array of host metabolic changes. 19, 20 Besides promoting steatosis and fibrosis progression, the presence of IR has been shown to impair treatement response and, viceversa, regress following successful treatment outcome.
Several studies have assessed IR in hepatitis C patients before and after interferon therapy. Petit et al. report that IR in nondiabetic HCV-infected patients was related to grading of liver fibrosis and may occur early in the course of HCV infection. 21 In a study including 260 HCV-infected subjects, Hui et al. found that HCV may induce IR irrespective of the severity of liver disease and that genotype 3 had a significantly lower HOMA-IR than other genotypes. 22 On the other hand, another study found that median HOMA-IR was significantly higher in patients with genotype 1 related steatosis than in those with genotype 3 related steatosis. 23 Irrespective of the genotype, higher HCV RNA levels were associated with the presence of IR and, accordingly, the severity of hepatic steatosis, 24, 25 where treatment and clearance of HCV improved IR. [26] [27] [28] Regarding the impact of HCV infection on the development of T2DM, a meta-analysis of 34 studies found a positive correlation between HCV infection and increased risk of T2DM in comparison to the general population in both retrospective and prospective studies. 29 Studies investigating the association between HCV and IR, and their key findings, are summarized in Table 1 .
HCV and hepatic steatosis
Hepatic steatosis was reported to be a histologic feature of non-A, non-B (NANB) hepatitis several years before hepatitis C testing was available, and it was considered common enough to be used as a diagnostic aid in the absence of serological diagnostic tests for hepatitis C. 55, 56 Steatosis occurs in 40%-86% of patients with chronic hepatitis C, and its frequency varies with genotype. [16] [17] [18] As already mentioned, steatosis is more common in genotype 3 infection, where it occurs in 73% of patients, while the prevalence of steatosis in patients infected with other genotypes is around 50%. [16] [17] [18] Infection with HCV genotype 3 is also associated with higher steatosis scores than in other genotypes, even in the absence of the metabolic risk factors associated with NAFLD, and there is a significant correlation between the degree of steatosis and the HCV RNA viral load. 57, 58 It has also been demonstrated in patients infected with HCV genotype 3 that steatosis can improve and even disappear following successful treatment with interferon (IFN) and ribavirin (RBV). 58 Recent studies investigating the role of a singlenucleotide polymorphism near the IL28B gene found that steatosis is less prevalent in carriers of the IL28B CC genotype, who also show less pronounced disturbances of lipid metabolism and a favorable response to IFN therapy. 59 Studies investigating the association between HCV and hepatic steatosis, and their key findings, are summarized in Table 2 .
Pathogenesis of insulin resistance and steatosis in HCV infection
The pathogenesis of IR and steatosis in HCV infection is a very intriguing problem, and extensive research of this topic has been undertaken. Different pathogenetic mechanisms have been proposed to explain the development of IR in HCV infected patients. [90] [91] [92] [93] [94] [95] In vitro and animal studies have greatly contributed to our understanding of both lipid and glucose metabolism alterations induced by HCV. Glucose transporter 2 (GLUT2), responsible for transporting glucose to hepatocytes, is downregulated by the HCV core protein, while the overproduction of tumor necrosis factor alpha (TNF-a), induced by HCV infection, inhibits insulin receptor substrate (IRS) and phosphatidylinositol 3 kinase (PI3K) via suppressor of cytokine sign-aling (SOCS)-3. These impairments of intracellular insulin signaling could block GLUT-4 activation, reducing the uptake of glucose by cells. [96] [97] [98] Other cytokines besides TNF-a, such as IL-6 as well as a number of adipokines, have been shown to play a part in IR and steatosis pathogenesis of NAFLD, and evidence on their influence in HCV-induced metabolic changes continue to grow.
99,100 HCV infection has also been suggested to cause mitochondrial dysfunction and endoplasmic reticulum impairment, while the genotype 3 HCV core protein has been shown to downregulate peroxisome proliferator activating receptor (PPARg) and upregulate SOCS-7, leading to further impairment of insulin signaling. [101] [102] [103] As for human studies, in a landmark study using liver biopsy specimens (LBS) obtained from nonobese, nondiabetic HCVinfected patients, HCV inhibited the insulin-stimulated tyrosine phosphorylation of hepatic insulin receptor substrate-1 (IRS-1), resulting in inhibition of the PI3K-Akt pathway, a key transducer of the insulin metabolic signal.
104,105 HCV (continued ) core protein was thus shown to impair hepatocyte insulin signaling by increasing cytokine production, predominantly TNF-a, activating SOCS, and inhibiting IRS through several mechanisms. All these mechanisms are probably responsible for hepatic IR. However, there is also evidence of significant peripheral IR in HCV infection. Milner et al., using a hyperinsulinemiceuglycemic clamp, found no difference in hepatic glucose production and nonesterified free fatty acids suppresion with insulin between CHC patients and controls, suggesting IR is predominantly in muscles. 20 Vanii et al. approximated the contribution of peripheral IR in CHC to reach 80%. 19 The role of liver-derived circulating factors (hepatokines), as possible mediators of the liver-muscle crosstalk, has yet to be fully elucidated. 106 The development of steatosis is also probably a result of several mechanisms. Both HCV induced and host related IR as well as metabolic factors are important for its development; it is also, however, a consequence of derangements of lipid metabolism caused directly by HCV. 16 The influence of HCV on cholesterol and lipogenesis pathways of hepatocytes is a crucial part of its life cycle. HCV core BMI, body mass index; CHC, chronic hepatitis C; HBV, hepatitis B virus; HCV, hepatitis C virus; LBS, liver biopsy specimens; NANB, non-A, non-B; NAFLD, non-alcoholic fatty liver disease; SVR, sustained viral response; IR, insulin resistance.
protein plays a major role in the replication process by inducing accumulation of lipid droplets as well as lipogenic gene and protein activity, consequently manifesting as hepatic steatosis. 107 Main mechanisms of HCV-induced hepatic steatosis include promotion of lipogenesis, impairment of mitochondrial lipid oxidation, and decreased microsomal triglyceride transfer protein (MTTP) activity. 108, 109 The activity of the HCV core protein decreases the expression and activity of the nuclear PPAR-a/g, which, besides being strongly involved in lipid and lipoprotein metabolism, seem to have a protective effect against hepatic inflammation and fibrosis. The analysis of PPAR-a expression in LBS of 86 untreated patients with HCV and controls found it to be deeply impaired. 110 The HCV core protein also induces hepatic fat accumulation by activating the sterol regulatory elementbinding protein-1c (SREBP-1c), a transcription factor regulating lipogenesis. 111 A study in transgenic mice expressing the full HCV protein repertoire showed maturational activation and nuclear translocation of SREBP-1c, resulting in increased lipogenic enzyme transcription. 112 The factors involved in pathogenesis of metabolic changes in HCV infection as well as clinical outcomes are shown in Fig. 1 .
Clinical consequences of hepatitis C associated steatosis and IR
The presence of both steatosis and IR in CHC may affect fibrosis and therapy outcomes as well as promote atherosclerosis and hepatic malignancy.
Liver fibrosis severity and progression are associated with hepatic steatosis and can be used as a clinically relevant parameter regarding starting and prioritizing treatment in CHC patients. 77, 82, 113, 114 IR, independent of other factors, is significantly associated with HCC development in patients with CHC. 44 Of further clinical relevance, primarily in areas where IFN-free regimens with direct-acting antivirals are not yet the standard of care, is the fact that IR has been shown to affect negatively responses to IFN treatment, effectively lowering sustained viral response (SVR) rates irrespective of genotype. 115 A review by Negro lists a number of conflicting studies regarding the impact of chronic HCV infection on cardiovascular morbidity. 116 It is not yet clear if the reported conditions and observations, such as increased incidence of coronary artery disease, stroke rate, and carotid plaque formation, are a result of a systemic chronic inflammation, direct viral action, or a consequence of IR.
The intricacies of the pathogenesis of IR, hepatic steatosis, and metabolic syndrome are not yet fully understood, and the fact that HCV is able to induce such changes and play a part in such a complex interplay of metabolic processes means it should remain an important focus of research, even as new therapies promise to make hepatitis C an easily managable condition.
Conclusions
Many epidemiological, clinical, and experimental studies have shown that HCV infection is strongly associated with liver steatosis, IR, and the development of T2DM. Our overview of available clinical data further establishes this premise and, with very few exceptions, shows the presence and strength of this association across various groups of patients, providing a strong foothold for future consideration of this topic. The severity of hepatic steatosis in CHC arises from the combination of several host features (like visceral obesity, genetic predisposition, medication use, and alcohol consumption) and viral factors (including genotype, viral load, and gene mutations), which interfere with lipid metabolism within the hepatocytes or promote IR in the liver and peripheral tissues.
The presence and severity of HCV associated steatosis and IR impact liver fibrosis severity and progression, lower rates of response to interferon-based therapy, promote HCC development, and probably increase cardiovascular morbidity.
The recognition of the link between HCV, steatosis, and MS is important for improved patient treatment and care, and many unresolved issues make it an intriguing area of future research.
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